Cargando…

Multicenter real‐world data of patients harboring rare mutations other than EGFR or ALK in advanced or metastatic non‐small cell lung cancer

BACKGROUND: Studies on the application of targeted therapies for patients with non‐small cell lung cancer (NSCLC) who harbor rare genetic mutations are ongoing. In the present study, we investigated the real‐world data of NSCLC patients who harbor rare mutations. METHODS: We retrospectively analyzed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Su Yeon, Kim, Young Chul, Lee, Kye Young, Lee, Sung Yong, Lee, Shin Yup, Lee, Min Ki, Lee, Jeong Eun, Jang, Seung Hun, Jang, Tae‐Won, Choi, Chang Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807245/ https://www.ncbi.nlm.nih.gov/pubmed/34881519 http://dx.doi.org/10.1111/1759-7714.14266

Ejemplares similares

Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea
por: Kim, Taeyun, et al.
Publicado: (2021)

Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping
por: Kim, Hye-Ryoun, et al.
Publicado: (2013)

Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
por: Ahn, Jin Woo, et al.
Publicado: (2014)

Targeted Next-Generation Sequencing Analysis Predicts the Recurrence in Resected Lung Adenocarcinoma Harboring EGFR Mutations
por: Kim, In Ae, et al.
Publicado: (2021)

Bilateral Ovarian Metastases from ALK Rearranged Non-Small Cell Lung Cancer
por: Lee, Kyung Ann, et al.
Publicado: (2014)

Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
por: Lee, Sung Yong, et al.
Publicado: (2021)

Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion
por: Woo, Chang Gok, et al.
Publicado: (2020)

Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors
por: Kim, Jehun, et al.
Publicado: (2023)

Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non–Small Cell Lung Cancer: Updated Analysis of the RESET Study
por: Kim, Taeyun, et al.
Publicado: (2023)

Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Lee, Jae Cheol, et al.
Publicado: (2013)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
por: Pisano, Chiara, et al.
Publicado: (2022)

Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing
por: Park, Mi-Young, et al.
Publicado: (2017)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers
por: Lee, Boram, et al.
Publicado: (2016)

P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement
por: Kim, Hee Joung, et al.
Publicado: (2015)

A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation‐positive non‐small cell lung cancer (stage III) who have not progressed following definitive, platinum‐based, chemoradiation therapy (PLATINUM trial)
por: Choi, Juwhan, et al.
Publicado: (2022)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Lewis, Whitney E., et al.
Publicado: (2021)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
por: Lee, Ki-Chang, et al.
Publicado: (2021)

Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutation
por: Jang, Seung Hun
Publicado: (2014)

Clinical impact of rebiopsy among patients with epidermal growth factor receptor‐mutant lung adenocarcinoma in a real‐world clinical setting
por: Nam, Yunha, et al.
Publicado: (2021)

Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
por: Park, Cheol‐Kyu, et al.
Publicado: (2020)

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
por: Tanaka, Hisashi, et al.
Publicado: (2012)

Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
por: Lee, Jang Ho, et al.
Publicado: (2023)

Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients
por: Hur, Jae Young, et al.
Publicado: (2018)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
por: Huang, Ming-Hung, et al.
Publicado: (2022)

Effect of Accreditation on the Accuracy of Diagnostic Hematologic Tests: Standard Deviation Index Analysis
por: Yoon, Young Ahn, et al.
Publicado: (2018)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
por: Jung, Hyun Ae, et al.
Publicado: (2020)

104P Exploring the real-world impact of COVID-19 on first line (1L) treatment and management of EGFR-wild type (EGFR-WT) and ALK-wild type (ALK-WT) metastatic non-small cell lung cancer (mNSCLC) across Europe
por: Bailey, H., et al.
Publicado: (2021)

Gefitinib in Selected Patients with Pre-Treated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, Non-Randomized Study (SELINE)
por: Lee, Kwan-Ho, et al.
Publicado: (2012)

The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas
por: Kim, Hyungjin, et al.
Publicado: (2019)

The association of (18)F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients
por: Kim, Seong-Jang, et al.
Publicado: (2010)

Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations
por: Kim, Ho Cheol, et al.
Publicado: (2019)

Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015)

Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
por: Kyi, Chrisann, et al.
Publicado: (2021)

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
por: Kim, In Ae, et al.
Publicado: (2018)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options
por: Desai, Arpita, et al.
Publicado: (2016)

Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
por: Kwon, Ji-Hyun, et al.
Publicado: (2019)

Long Distance Runners Present Upregulated Sweating Responses than Sedentary Counterparts
por: Lee, Jeong-Beom, et al.
Publicado: (2014)

Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series
por: Shin, Hong-Joon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_olh5dg5gq5ga4fudhjoa35t6oq